Stock MACK MERRIMACK PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Merrimack Pharmaceuticals, Inc.

Equities

MACK

US5903282094

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
14.73 USD 0.00% Intraday chart for Merrimack Pharmaceuticals, Inc. +0.34% +9.84%
Mar. 27 Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT
Mar. 07 Merrimack Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company. The Company does not have any ongoing research or development activities and is seeking potential acquirers for its remaining preclinical and clinical assets. The Company is entitled to receive contingent payments related to its sale of ONIVYDE to Ipsen S.A. and also its contingent payments related to its sale of MM-121 and MM-111 to Elevation Oncology, Inc. Its payments are payable by Ipsen upon approval by the United States Food and Drug Administration (FDA) of ONIVYDE for certain additional clinical indications. ONIVYDE is approved by the FDA in combination with fluorouracil (5-FU) and leucovorin (LV) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. The Company’s wholly owned subsidiaries include Merrimack Pharmaceuticals UK Limited and Merrimack Securities Corporation.

Number of employees: 27

Managers

Managers TitleAgeSince
Ulrik Nielsen FOU
 Founder 52 92-12-31
Gary Crocker CEO
 Chief Executive Officer 72 03-12-31
Timothy R. Surgenor IRC
 Investor Relations Contact - -

Members of the board

Members of the board TitleAgeSince
Gary Crocker CEO
 Chief Executive Officer 72 03-12-31
Noah Gabriel Levy BRD
 Director/Board Member 45 19-09-18
Ulrik Nielsen FOU
 Founder 52 92-12-31
Eric David Andersen BRD
 Director/Board Member 46 19-09-18
Ana Radeljevic BRD
 Director/Board Member 44 22-06-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 14,531,760 14,355,601 ( 98.79 %) 0 98.79 %

Shareholders

NameEquities%Valuation
Western Standard LLC
14.95 %
2,172,513 14.95 % 32 M $
Newtyn Management LLC
12.89 %
1,873,694 12.89 % 28 M $
BlackRock Advisors LLC
4.937 %
717,451 4.937 % 11 M $
Vanguard Fiduciary Trust Co.
4.191 %
608,954 4.191 % 9 M $
Madison Avenue Partners LP
3.806 %
553,085 3.806 % 8 M $
Adar1 Capital Management LLC
3.781 %
549,418 3.781 % 8 M $
Dimensional Fund Advisors LP
2.998 %
435,645 2.998 % 6 M $
Sepio Capital LP
2.110 %
306,680 2.110 % 5 M $
Sio Capital Management LLC
1.985 %
288,466 1.985 % 4 M $
Geode Capital Management LLC
1.789 %
259,946 1.789 % 4 M $

Company contact information

Merrimack Pharmaceuticals, Inc.

One Broadway 14th Floor

02142, Cambridge

+

http://www.merrimackpharma.com
address Merrimack Pharmaceuticals, Inc.(MACK)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MERRIMACK PHARMACEUTICALS, INC. Stock Merrimack Pharmaceuticals, Inc.
+9.84% 214M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 42.11B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 40.08B
MODERNA, INC. Stock Moderna, Inc.
+8.49% 40B
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 26.87B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 24.58B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.44B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 11.94B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 11.66B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.01B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MACK Stock
  4. Company Merrimack Pharmaceuticals, Inc.